Golden
YourChoice Therapeutics

YourChoice Therapeutics

YourChoice Therapeutics is a biotechnology company founded in 2018 is developing contraceptives for men and women. The technology for their non-hormonal contraceptive products arose from research at the University of California, Berkeley.

All edits

Edits on 3 Apr 2019
Dawson Sewell
Dawson Sewell edited on 3 Apr 2019 1:14 pm
Edits made to:
Infobox (+2 properties)
Article (+876/-653 characters)
Further reading (+1 rows) (+5 cells) (+195 characters)
Related Topics (+1 topics)

Article

YourChoice Therapeutics was one of the 2018 CITRIS Foundry Startups. One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

YourChoice Therapeutics is a biotechnology company that was one of the 2018 CITRIS Foundry Startups founded by Akash Bakshi, Nadja Mannowetz, and Polina Lishko. 

...

One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

Funding

Seed

On January 1, 2019 YourChoice Therapeutics completed a seed funding round with $550,000 in funding from Y Combinator. 

Further reading

Title
Author
Link
Type

Regulation of the sperm calcium channel CatSper by endogenous steroids and plant triterpenoids

Pnas

Web

YourChoice Therapeutics is developing unisex, non-hormonal birth control

Kate Clark

Web

Infobox

Related Topics

Edits on 18 Mar 2019
Golden AI
Golden AI edited on 18 Mar 2019 10:19 pm
Edits made to:
Infobox (+2 properties)

Infobox

Accelerator
Accelerator Batch
Edits on 21 Feb 2019
Melanie Manipula
Melanie Manipula approved a suggestion from Golden's AI on 21 Feb 2019 2:06 am
Edits made to:
Infobox (+1 properties)

Infobox

Edits on 18 Jan 2019
Meredith Hanel
Meredith Hanel approved a suggestion from Golden's AI on 18 Jan 2019 8:09 pm
Edits made to:
Article (+14/-14 characters)

Article

YourChoice Therapeutics was one of the 2018 CITRIS Foundry Startups. One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motilitysperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

Meredith Hanel
Meredith Hanel approved a suggestion from Golden's AI on 18 Jan 2019 8:09 pm
Edits made to:
Article (+5/-5 characters)

Article

YourChoice Therapeutics was one of the 2018 CITRIS Foundry Startups. One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

Meredith Hanel
Meredith Hanel edited on 18 Jan 2019 8:09 pm
Edits made to:
Infobox (+2 properties)
Meredith Hanel
Meredith Hanel edited on 18 Jan 2019 7:29 pm
Edits made to:
Description (+238 characters)
Article (+653 characters)
People (+3 rows) (+6 cells) (+90 characters)
Further reading (+1 rows) (+3 cells) (+137 characters)
Categories (+1 topics)
Topic thumbnail

YourChoice Therapeutics

YourChoice Therapeutics is a biotechnology company founded in 2018 is developing contraceptives for men and women. The technology for their non-hormonal contraceptive products arose from research at the University of California, Berkeley.

Article

YourChoice Therapeutics was one of the 2018 CITRIS Foundry Startups. One of their technologies is a “molecular condom” concept where an active compound inhibits sperm motility preventing it from fertilizing the egg.The molecular target on the sperm is CatSper, a sperm-specific calcium ion channel that initiates a motility pattern called hyperactivation needed for fertilization. The research group discovered that the extracellular protein, ABHD2 that regulates CatSper activity can be bound by the plant-derived compound lupeol. This prevents the sperm from transitioning to hyperactivation and the affected sperm are incapable of fertilizing an egg.

People

Name
Role
Related Golden topics

Akash Bakshi

Co-Founder, CEO



Nadja Mannowetz

Co-Founder, CSO



POLINA LISHKO

Founder, Consultant



Further reading

Title
Author
Link
Type

Regulation of the sperm calcium channel CatSper by endogenous steroids and plant triterpenoids



Web

Categories

Meredith Hanel"Initial topic creation"
Meredith Hanel created this topic on 18 Jan 2019 6:59 pm
Edits made to:
Topic thumbnail

 YourChoice Therapeutics

YourChoice Therapeutics is a biotechnology company founded in 2018 is developing contraceptives for men and women. The technology for their non-hormonal contraceptive products arose from research at the University of California, Berkeley.

No more activity to show.